Gablofen (intrathecal baclofen) is a U.S. Food and Drug Administration (FDA) approved therapy for treatment of severe spasms caused by problems in the brain or spine in adults and children over age 4. It is designed for people with diseases such as multiple sclerosis (MS) who can not tolerate baclofen by mouth or do not experience relief from tablets.

Intrathecal baclofen therapy (ITB) is an established and widely accepted treatment option. Because it is administered directly into the intrathecal space (injected), the results are better at lower doses than oral medications, and with fewer adverse effects.

ITB therapy consists of a pump with a chamber that is placed by a surgeon under the skin of the stomach. It is connected to the intrathecal space by a small tube. The chamber is filled with liquid baclofen. The pump is programmed to distribute the medicine around the clock for controlling spasticity as needed.

This medicine has a black box warning that appears on the prescription drug’s label to call attention to serious or life-threatening risks. Abrupt discontinuation of injected Gablofen may cause high fever, altered mental status, an increase in spasms, and muscle rigidity. In rare cases, abruptly stopping the medication has led to organ failure and death. Careful attention to programming, monitoring the pump, refill scheduling, and pump alarm care is needed in order to avoid abrupt discontinuation of the drug.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

MS News that Caught My Eye Last Week: Stimulator for Spasticity, Tysabri Dosing Trial, Mobility Devices Contest, Stem Cell Phase 2 Trial

WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity I’m one of the many people with multiple sclerosis (MS) for whom spasticity is a significant problem. This is a nonmedicinal approach to dealing with it. I hope it doesn’t take too long to make this electrical stimulator available and, once it is, that […]

WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity

WeHealth by Servier and PathMaker Neurosystems have established a new partnership to develop and commercialize the first neuromodulation technology for noninvasive treatment of spasticity, the companies announced. The agreement establishes an exclusive worldwide distribution arrangement, except for the U.S. and Japan, for PathMaker’s MyoRegulator. The MyoRegulator uses two pairs of disposable skin-surface electrodes that deliver synchronized stimulation […]

Cannabis-based Sublingual Tablet to Enter Trials in Israel as Possible Spasticity Treatment, OWCP Says

OWC Pharmaceutical Research is planning new clinical studies to evaluate the activity and safety of its cannabinoid-enriched sublingual soluble tablet. The company announced that an Institutional Review Board (IRB) in Israel approved its request to conduct a safety and tolerability trial there. The company also is asking to amend the study design, allowing the trial to […]

#ECTRIMS2018 — Data from 2 EU Trials Shows Effectiveness of Cannabidiol Spray in Treating Spasticity

Data from two European trials — a real-life study in Italy, and a long-term Czech trial looking at impact on cognition — supported the efficacy of a widely approved cannabinoid spray in treating moderate to severe spasticity (muscular stiffness or involuntary spasms) in multiple sclerosis (MS) patients who failed to benefit from other spasticity treatments. […]

Spasticity Scales May Not Be Sufficiently Informative of Sativex Benefits in MS Patients, Small Study Suggests

Spasticity scales may be insufficient to reflect the actual benefits of Sativex (nabiximols) treatment on spasticity symptoms in people with multiple sclerosis (MS), according to a small case series study. The results support the need to conduct a more extensive and functional examination to clarify treatment responses and help optimize treatment decisions. The study, “Variability […]

Using Medical Marijuana for MS Symptoms May Affect Your Employment

Ohio, my home state, is wrestling with the nuances of medical marijuana laws that become effective on Sept. 8, 2018. My husband’s work email had an important notice from the Bureau of Worker’s Compensation (BWC) about this pending change, and as I read it, I thought that nothing really changed. Although medical marijuana legalization has […]

MedChew RX Shows Stability and Potential for Effectiveness in Early Tests, Company Reports

AXIM Biotech announced that tests done on its cannabinoid-based chewing gum — MedChew Rx — showed both product stability and effective release of medicinal molecules, with a high percentage of its pharmaceutical ingredients available. These test results may be of importance, as the company is planning to bring MedChew Rx into clinical trials as a treatment for pain and spasticity in multiple sclerosis […]

Multiple Sclerosis Patients Identify Symptoms that Worsen Quality of Life

Loss of health-related quality of life is caused mostly by balance problems, muscle stiffness, and depression in people with relapsing-remitting multiple sclerosis (RRMS), and for those with progressive MS, the causes are muscle rigidity, paralysis, weakness, and pain, according to a study based on patient-reported outcomes. The study, “The disease burden of Multiple Sclerosis from the individual […]

Axim Biotech Given Patent for Method of Making Medical Cannabis Compound

Axim Biotech announced that its way of extracting and purifying THC (delta-9-tetrahydrocannabinol) — an active compound in medical cannabis — has been approved to receive a patent. The notice of allowance for patient No. 15/146668 came in letter from the United States Patent and Trademark Office (USPTO), Axim said in a press release. Axim specializes in the research […]